Advancing Global MedTech Integration: HTDK to Participate in AdvaMed MedTech Conference 2025

This October, the world’s premier medical technology event—AdvaMed MedTech Conference 2025—will take place in San Diego, USA. As a leading commercialization partner for high-value medical devices, HTDK will participate in the event with an executive delegation led by CEO Teresa and Board Director William, alongside the core business development team. HTDK will engage deeply with top global MedTech companies to explore the future of the industry and further accelerate the localization of innovative medical technologies in China.

AdvaMed (Advanced Medical Technology Association) is the world’s most influential organization for medical technology innovation. Since its founding in 1974, AdvaMed has played a pivotal role in guiding the development of the global MedTech industry. Its members include Fortune 500 companies such as Medtronic, BD, Siemens Healthineers, Johnson & Johnson, Stryker, and Boston Scientific, as well as numerous high-potential, innovation-driven small and medium-sized enterprises.

AdvaMed member companies’ products represent over 80% of the U.S. and more than 40% of the global medical device market. Notably, approximately 40% of mature MedTech products currently marketed in the U.S. and Europe have yet to enter the Chinese market—presenting significant growth potential for HTDK’s global partnerships.

As one of the largest foreign-invested commercialization service platforms for medical technologies in China, HTDK is dedicated to delivering end-to-end, localized solutions for international MedTech enterprises. Our comprehensive service offerings include:

• Manufacturing
• Clinical Evaluation and Product Registration
• Importation & Exportation
• Bonded and Non-bonded Warehousing and Fulfilment
• Commercial Platform
• Inventory management
• Clinical Adoption
• Post-Market Surveillance

In recent years, HTDK has significantly expanded its business scope. Originally focused on specialty areas such as ophthalmology, neurology, orthopedics, respiratory care, and in vitro diagnostics, the company has extended its services into aesthetic medicine and dental care, meeting the evolving needs of both professional and consumer MedTech markets.

At this year’s conference, HTDK’s leadership team will also contribute to high-level industry discussions on key topics such as U.S.-China tariff policy, regulatory strategies, and market access pathways.

Amid a complex and uncertain global economic landscape, HTDK continues to identify substantial opportunities through its deep industry expertise, professional service capabilities, and robust commercialization infrastructure in China. Through its participation in the AdvaMed MedTech Conference 2025, HTDK looks forward to forming new strategic alliances with global MedTech leaders and accelerating the entry of cutting-edge medical technologies into the Chinese market—delivering meaningful impact to patients across the country.